Clinical Trial Update: Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on IM19 CAR-T cells evaluating safety and efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) across Phase 1 and Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• IM19 CAR-T Cells

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Leukemia | Phase 1, Phase 2 | Status: UNKNOWN